Prescriber Scope of Practice for Insomnia in Georgia

You’re considering treating insomnia patients via telehealth — or maybe you already do, and you’re wondering if you’re actually compliant with the maze of federal DEA rules and state prescribing laws. Let’s cut through the noise.

The short answer: Yes, psychiatrists and PMHNPs can legally prescribe insomnia medications (including controlled substances like Ambien, Lunesta, and benzodiazepines) via telehealth through December 31, 2026, under current federal DEA flexibilities. But there are critical caveats — especially around state scope-of-practice laws, PDMP requirements, and some state-specific telehealth prescribing restrictions.

If you’re treating insomnia patients across state lines or expanding into new markets, understanding these rules isn’t just about compliance — it’s about protecting your license and building a sustainable practice. Here’s what you actually need to know.

The Federal Framework: DEA Telehealth Flexibilities (And What’s Coming)

Where We Stand in 2026

The Ryan Haight Act of 2008 normally requires an in-person medical evaluation before prescribing any controlled substance via the internet. For years, this effectively killed telehealth prescribing of medications like zolpidem (Ambien) or temazepam — unless the patient had already been seen face-to-face.

COVID changed everything. In March 2020, the DEA suspended the in-person requirement to maintain access to care during the pandemic. That waiver has been extended four times — most recently through December 31, 2026. This means right now, you can legally prescribe Schedule II–V controlled substances to new patients via audio-video telehealth without ever seeing them in person, as long as you meet standard-of-care requirements and comply with state law.

What Medications Does This Cover for Insomnia?

Most insomnia medications are Schedule IV controlled substances:

• Non-benzodiazepine hypnotics (‘Z-drugs’): Zolpidem (Ambien), eszopiclone (Lunesta), zaleplon
• Benzodiazepines: Temazepam (Restoril), triazolam (Halcion)
• Orexin receptor antagonists: Suvorexant (Belsomra), lemborexant (Dayvigo)

These are all covered under the current DEA telehealth flexibility. You can initiate treatment, write the prescription electronically, and the patient can fill it at their local pharmacy — all from a video consultation.

Non-controlled options like trazodone, doxepin (low-dose), or ramelteon (melatonin receptor agonist) have no special DEA restrictions and can be prescribed via telehealth indefinitely.

The Permanent Rule That’s Coming

The DEA is working on a final regulatory framework to replace these temporary flexibilities. In January 2025, the agency proposed a Special Registration system:

• For Schedule III–V substances (which includes most insomnia meds): Any DEA-registered practitioner could apply for a ‘Telemedicine Special Registration’ to prescribe these medications virtually without an in-person exam.
• For Schedule II substances (stimulants, some opioids): An ‘Advanced Telemedicine Registration’ would be available only to certain specialists — including psychiatrists — with a national PDMP system as a safeguard.

This hasn’t been finalized yet. The December 2026 extension is designed to give the DEA time to implement this framework without disrupting patient care. But the writing is on the wall: permanent telehealth prescribing authority is coming, likely with a registration requirement and some guardrails.

Bottom line: For now, you’re operating under temporary but legal federal permissions. Plan for a future where you’ll need a special DEA telemedicine registration, but don’t expect the in-person requirement to return wholesale — the DEA has acknowledged that would ‘disrupt patient care’ and create backlogs.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist vs. PMHNP Scope: Who Can Do What?

Psychiatrists: Full Authority, Everywhere

If you’re a psychiatrist (MD or DO), treating insomnia is squarely within your scope in all 50 states. You can:

• Diagnose insomnia and comorbid psychiatric conditions
• Provide behavioral interventions (CBT-I, sleep hygiene counseling)
• Prescribe any insomnia medication, controlled or otherwise
• Practice via telehealth if you’re licensed in the patient’s state

No supervision required. No collaborative agreement. No restrictions on Schedule IV prescribing (and you’re one of the few provider types who can tele-prescribe Schedule II under the proposed DEA rules, if that ever becomes relevant).

Your main regulatory obligations are:

• State medical license in the patient’s state
• DEA registration (and state controlled substance license where required)
• PDMP checks before prescribing controlled substances (requirements vary by state — see below)
• Standard-of-care documentation (sleep history, ruling out medical causes, treatment plan)

PMHNPs: It Depends on Your State

Psychiatric-Mental Health Nurse Practitioners are fully capable clinically of managing insomnia — but your legal authority varies dramatically by state.

Full Practice Authority (FPA) States:

• New York: After 3,600 hours of supervised practice, you can practice and prescribe independently (including controlled substances).
• Illinois: After 4,000 hours and additional CE, you can obtain FPA and prescribe independently.
• California: AB 890 created a pathway for experienced NPs to practice independently; by 2026, many PMHNPs will qualify.

In these states, you can run an independent insomnia telehealth practice, prescribe Schedule IV sleep meds, and build your own patient panel without physician oversight.

Reduced/Restricted Practice States:

• Pennsylvania: You need a collaborative agreement with a physician to prescribe anything. The agreement must specify your prescriptive authority for controlled substances.
• Texas: You need a Prescriptive Authority Agreement with a supervising physician. Texas law also prohibits NPs from prescribing Schedule II controlled substances outside hospital/hospice settings (not relevant for most insomnia meds, but worth knowing).
• Florida: PMHNPs require a supervising physician protocol. Florida’s 2020 ‘autonomous APRN’ law excluded psychiatric NPs — there’s pending legislation (SB 758) to change this, but as of early 2026, supervision is still required.

The practical impact:

• In FPA states, you can market directly to patients and build your own practice.
• In restricted states, you need to work within a group practice or platform (like Klarity) that has physician oversight built in. You’re still seeing and managing the patients — there’s just a supervising MD on record.

State-by-State Telehealth Prescribing Rules: The Details That Matter

Federal law gives you permission to prescribe controlled substances via telehealth. State law determines how you do it — and sometimes whether you can at all. Here’s what you need to know for the priority markets:

California: Permissive, With PDMP Vigilance

The good: No state-level ban on telehealth controlled substance prescribing for Schedule IV insomnia meds. California explicitly allows telehealth exams to substitute for in-person visits if the standard of care is met.

The catch: California discourages prescribing Schedule II controlled substances via telehealth without a prior in-person exam (old Medical Board guidance targeting pill mills). Not relevant for insomnia, but worth knowing if you ever prescribe stimulants.

PDMP requirement: You must check California’s CURES database before prescribing any Schedule II–IV controlled substance for the first time, and at least every four months if treatment continues. Electronic prescribing is mandatory for all controlled substances (since 2022).

NP status: California’s AB 890 is gradually expanding NP independence. Experienced PMHNPs (3+ years in a group setting) can now qualify to practice independently. If you’re an NP in California, this is your path to building an independent insomnia practice.

Market opportunity: California has massive demand, especially in rural areas. Telehealth parity laws require insurers (including Medi-Cal) to cover tele-mental health at the same rate as in-person. Spanish and Chinese language capabilities are in high demand.

Texas: Open for Insomnia, Closed for Pain

The good: Texas explicitly allows telehealth prescribing of controlled substances for most conditions. The 2017 reforms (SB 1107) eliminated the old in-person requirement for establishing a patient relationship.

The catch: Texas prohibits prescribing controlled substances via telehealth for chronic pain management. This rule targets opioid prescribing but is written broadly. It does not apply to insomnia — insomnia is a sleep disorder, not pain management.

PDMP requirement: You must check Texas’s PMP AWARxE system before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol. As of 2021, this was expanded to all Schedule III–V drugs, so you’ll need to check before prescribing zolpidem. Electronic prescribing is mandatory.

NP status: Texas is restrictive. PMHNPs need a supervising physician and cannot prescribe Schedule II controlled substances in outpatient settings (hospital/hospice only). For Schedule IV insomnia meds, you can prescribe under your Prescriptive Authority Agreement.

Market opportunity: Texas has huge rural populations underserved by psychiatrists. Telehealth is widely accepted post-2017. Just ensure your documentation clearly shows you’re treating a sleep disorder, not chronic pain.

Florida: The ‘Psychiatric Exception’ Is Your Friend

The good: Florida allows out-of-state providers to register as telehealth providers without full Florida licensure — a unique program that makes multi-state practice easier.

The catch: Florida law prohibits prescribing controlled substances via telehealth except for: (1) treatment of a psychiatric disorder, (2) inpatient hospital care, (3) hospice, or (4) nursing home residents.

Why this matters for insomnia: Insomnia qualifies as a psychiatric disorder (it’s in the DSM-5 as ‘Insomnia Disorder’). Document this appropriately and you’re covered. Florida has explicitly allowed telehealth prescribing of benzodiazepines and stimulants for mental health conditions under this exception — Schedule IV sleep medications fit the same framework.

PDMP requirement: You must check Florida’s E-FORCSE database before every prescription of a controlled substance to a patient age 16+. This is stricter than most states (many only require checks on initial prescriptions).

NP status: Florida’s ‘autonomous APRN’ law excluded psychiatric NPs. PMHNPs still need a supervising physician protocol. Pending legislation (SB 758) may change this, but don’t count on it soon.

Market opportunity: Large elderly population with high insomnia rates. Snowbirds create year-round telehealth demand. Just ensure you’re framing insomnia treatment within a psychiatric/mental health context in your documentation.

New York: Progressive NP Laws, Strict PDMP Rules

The good: New York has no state restrictions on telehealth prescribing of controlled substances beyond federal requirements. The state strongly supports tele-mental health.

NP independence: New York’s NP Modernization Act (made permanent in 2022) allows experienced NPs to practice independently after 3,600 hours of supervised practice. This is a game-changer for PMHNPs building independent practices.

The catch: New York requires an ISTOP PDMP check before every prescription of a Schedule II, III, or IV controlled substance. Not just the first time — every time. This is one of the strictest PDMP requirements nationally. Electronic prescribing is mandatory for all prescriptions.

Market opportunity: New York City and suburbs have enormous demand but also high provider concentration. Upstate New York (rural areas) faces major shortages — telehealth can fill that gap. Strong insurance coverage for tele-mental health, including Medicaid.

Pennsylvania: No Special Telehealth Rules, But NP Collaboration Required

The good: Pennsylvania has no state-specific restrictions on telehealth prescribing of controlled substances. The Medical and Osteopathic Boards allow physician-patient relationships to be established via telehealth if standard of care is met.

NP status: Pennsylvania is a reduced-practice state. PMHNPs need a collaborative agreement with a physician that explicitly covers prescriptive authority for controlled substances. No independence pathway yet (legislative attempts have failed).

PDMP requirement: You must check Pennsylvania’s PDMP before prescribing any opioid or benzodiazepine initially and for every subsequent prescription or refill. If you’re using benzodiazepines for insomnia (temazepam, etc.), this applies. For Z-drugs like zolpidem, it’s not strictly mandated but recommended.

Market opportunity: Major urban centers (Philadelphia, Pittsburgh) plus large rural areas with limited access to psychiatrists. Telehealth is widely accepted, especially for mental health. If you’re an NP, you’ll need a collaborating physician in Pennsylvania — but there’s strong demand for services.

Illinois: NP Full Practice Authority + Telehealth-Friendly Laws

The good: Illinois offers Full Practice Authority for experienced NPs (4,000 hours + additional CE in specialty). Once you have FPA, you can prescribe controlled substances independently, including Schedule IV insomnia medications.

Telehealth: Illinois has strong telehealth parity laws and permanent audio-only coverage for mental health services. No special restrictions on controlled substance prescribing via telehealth.

PDMP requirement: Illinois requires PDMP checks before starting opioid therapy (mandatory as of 2018). For other controlled substances, it’s recommended but not strictly mandated. Most providers check for all controlled prescriptions to be safe.

Market opportunity: Chicago metro has huge demand; downstate Illinois (rural/small-town) faces major provider shortages. Progressive regulatory environment makes this an attractive state for telehealth expansion. NPs with FPA can build independent practices; newer NPs can work under collaborative agreements.

The Economics of Insomnia Telehealth: Why Patient Acquisition Matters

Here’s the reality nobody talks about: treating insomnia via telehealth is clinically straightforward, but building a patient pipeline is expensive and time-consuming.

The DIY Marketing Trap

Most providers starting an independent insomnia practice assume they can acquire patients cheaply through DIY marketing. The math doesn’t work:

SEO: Takes 6–12 months of consistent investment (content, backlinks, technical optimization) before you see meaningful traffic. Most solo providers don’t have the expertise or patience. Even then, you’re competing with giant directories and hospital systems.

Google Ads: Mental health keywords cost $15–40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked appointment is $200–400+ when you factor in:

• Ad spend and click costs
• Testing and optimization (failed campaigns)
• Staff time to handle and qualify leads
• No-show rates from cold leads
• Landing page development and maintenance

Directory Listings: Psychology Today charges a monthly subscription ($39.95–$59.95) and you’re competing with hundreds of other providers on the same search page. Zocdoc charges per booking ($35–100+ depending on specialty and market) plus monthly platform fees. Total monthly cost easily hits $500–1,000+ for modest patient flow.

Reality check: When you add it all up — agency/consultant fees, ad spend, staff time, failed campaigns, no-shows — acquiring a qualified psychiatric patient through DIY marketing typically costs $200–500+ all-in. And that’s after you’ve figured out what works, which can take months and thousands in wasted spend.

The Platform Model: Guaranteed ROI

This is where a platform like Klarity Health changes the economics entirely.

Instead of spending $3,000–5,000/month on marketing with uncertain results, you pay only when a qualified patient books with you. Klarity uses a pay-per-appointment model similar to Zocdoc, but with critical differences:

• Pre-qualified patients: Already matched to your specialty (insomnia, ADHD, anxiety) and availability
• No upfront marketing spend: No monthly subscriptions, no ad budget gambling
• No wasted spend on unqualified leads: Every patient who books has been screened and is ready for treatment
• Built-in telehealth infrastructure: No separate EHR, video platform, or billing system costs
• Both insurance and cash-pay flow: You choose your payer mix

The standard listing fee per new patient lead is transparent and competitive. More importantly, it’s guaranteed ROI — you only pay when a patient actually shows up.

For most providers, especially those starting out or scaling, this model removes all the patient acquisition risk. You focus on clinical care. The platform handles marketing, lead qualification, scheduling infrastructure, and patient matching.

When does DIY make sense? If you have:

• A marketing budget of $5,000+/month you can sustain for 6–12 months
• In-house expertise in SEO, PPC, and conversion optimization
• The patience to test and iterate for months before seeing results
• An established reputation or referral network to supplement paid marketing

For everyone else, paying a predictable per-appointment fee beats gambling on marketing channels any day.

Practical Compliance: What You Need to Do Tomorrow

Documentation Essentials

Telehealth doesn’t change the standard of care — you need the same clinical rigor as an in-person visit:

Initial evaluation:

• Detailed sleep history (onset, duration, frequency, patterns)
• Screen for medical causes (sleep apnea, restless legs, thyroid issues)
• Psychiatric comorbidities (depression, anxiety, PTSD)
• Substance use (alcohol, caffeine, other drugs)
• Current medications and allergies
• Prior treatments tried (behavioral and pharmacological)

Treatment plan:

• Document why you’re prescribing a controlled substance (e.g., ‘Patient has chronic insomnia disorder, DSM-5, unresponsive to sleep hygiene modifications and melatonin’)
• Start with lowest effective dose and shortest duration
• Discuss non-pharmacological options (CBT-I, sleep hygiene)
• Obtain informed consent about dependency risks with benzodiazepines/Z-drugs
• Schedule follow-up (typically 2–4 weeks for initial controlled substance prescriptions)

Florida-specific: Explicitly document that insomnia is being treated as a psychiatric disorder to fit within the telehealth controlled substance exception.

PDMP Compliance: State-by-State Checklist

Pro tip: Build PDMP checks into your EHR workflow. Most modern systems can integrate state PDMP databases or at least prompt you to check before e-prescribing.

E-Prescribing Requirements

Most states now mandate electronic prescribing for controlled substances (EPCS):

• California: Mandatory (since 2022)
• Texas: Mandatory (since 2021)
• New York: Mandatory (with limited exceptions)
• Pennsylvania, Florida, Illinois: Strongly encouraged; some insurers require it

You’ll need an EPCS-enabled prescribing system and identity proofing (two-factor authentication). If you’re not set up for this yet, it’s a prerequisite for controlled substance prescribing in most states.

FAQ: What Providers Actually Want to Know

Can I prescribe Ambien to a new patient I’ve never met in person?

Yes, through December 31, 2026, under the current DEA extension. After that, you’ll likely need a DEA telemedicine special registration, but the in-person requirement won’t return. Just ensure you’re licensed in the patient’s state and follow that state’s PDMP and documentation rules.

What happens if the DEA extension expires and I don’t have the special registration?

The DEA has extended the flexibilities four times specifically to avoid this scenario. If the extension were to lapse without a permanent framework in place, you’d technically revert to the Ryan Haight Act’s in-person requirement. In practice, the DEA has signaled it will implement the special registration system before any extension expires — they’ve explicitly stated that letting the flexibilities expire would ‘disrupt patient care.’

Do I need separate state controlled substance licenses?

Some states require it:

• Illinois: Separate state controlled substance license (ICS number)
• Texas, Florida: DEA number is sufficient, but check state requirements
• California, New York, Pennsylvania: DEA registration covers it

Check with your state’s medical board or board of nursing.

Can I prescribe benzodiazepines long-term for insomnia?

Clinically, benzodiazepines are not first-line for chronic insomnia due to tolerance and dependency risks. Most guidelines recommend short-term use (2–4 weeks) or intermittent dosing. From a regulatory standpoint, you can prescribe them longer-term if clinically justified and documented, but:

• Medical boards will scrutinize long-term benzo prescribing more heavily than Z-drugs
• PDMP checks are mandatory in most states for benzos (every prescription in some states)
• You should document attempts at non-pharmacological treatments and why alternatives aren’t appropriate

As a PMHNP in a restricted-practice state, can I still build a telehealth practice?

Absolutely, but you’ll need a collaborative agreement with a physician. Platforms like Klarity handle this by having supervising physicians on staff. You still see and manage the patients autonomously day-to-day — the collaboration is a legal framework, not a clinical micromanagement relationship. In practice, most NPs in collaborative settings operate very independently.

What if I’m licensed in multiple states — do I need to check multiple PDMPs?

If you’re treating a patient in State A, you check State A’s PDMP (and only State A’s, unless the state mandates checking neighboring states, which some do). Some states have interstate PDMP data sharing agreements, so you might see out-of-state prescriptions in the database. Always check the PDMP in the state where the patient is located at the time of the telehealth visit.

Can I prescribe Schedule II stimulants for patients with hypersomnia or narcolepsy via telehealth?

Under current federal rules (through 2026), yes. Under the proposed DEA permanent rules, Schedule II tele-prescribing would require an ‘Advanced Telemedicine Registration’ available only to certain specialists — psychiatrists are explicitly included in that category. PMHNPs would likely not qualify for Schedule II tele-prescribing under the proposed rules, but this is still being finalized.

For insomnia specifically, you rarely need Schedule II substances anyway (stimulants aren’t insomnia treatments; occasionally modafinil, which is Schedule IV, is used off-label for residual daytime sleepiness).

What’s my liability if I prescribe a sleep medication via telehealth and something goes wrong?

Your liability is the same as in-person practice: you’re held to the standard of care. As long as you:

• Conducted an appropriate evaluation (even if virtual)
• Ruled out serious medical conditions or made appropriate referrals
• Documented your clinical reasoning
• Prescribed within evidence-based guidelines
• Followed all DEA and state prescribing laws

…you’re on solid ground. Malpractice in telehealth is about clinical negligence, not the modality itself. Courts and medical boards have consistently held that telehealth is a legitimate practice setting if standard-of-care is met.

The bigger risk is regulatory violations — prescribing without proper licensure, skipping PDMP checks, or violating state telehealth prescribing bans. Those are license-threatening events.

The Bottom Line: Insomnia Telehealth Is Wide Open, If You Play by the Rules

Insomnia treatment via telehealth is not only legal — it’s becoming standard of care. The temporary DEA flexibilities that enabled this during COVID are being made permanent through a special registration system. State laws vary, but in most cases, the barriers are procedural (PDMP checks, documentation, licensure) rather than absolute prohibitions.

If you’re a psychiatrist: You have maximum flexibility. Get licensed in the states where you want to practice, follow their PDMP rules, document appropriately, and you can build a thriving insomnia telehealth practice.

If you’re a PMHNP: Your path depends on your state. In FPA states (New York, Illinois, soon California), you can practice independently. In restricted states (Texas, Florida, Pennsylvania), you’ll need physician collaboration — which platforms like Klarity provide as part of the infrastructure.

The real question isn’t whether insomnia telehealth is legal — it is. The question is whether you want to spend 6–12 months and thousands of dollars figuring out patient acquisition on your own, or plug into a system that delivers pre-qualified patients to your schedule and only charges when you see them.

For most providers, especially those starting out or scaling, the math is simple: guaranteed ROI beats gambling on marketing every time.

Ready to Treat Insomnia Patients Without the Marketing Headache?

Klarity Health connects psychiatrists and PMHNPs with patients who need insomnia treatment — already matched to your availability, pre-qualified, and ready to book. No upfront marketing spend. No wasted ad budget. No months of SEO waiting.

You focus on clinical care. We handle patient acquisition, compliance infrastructure, and scheduling. Pay only when a patient shows up.

Explore Klarity’s Provider Network →

Sources and References

1. DEA Press Release – ‘DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care’ (December 31, 2025). www.dea.gov
   Official announcement of the Fourth Temporary Rule extending telehealth controlled substance prescribing through December 31, 2026.

2. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access’ (January 16, 2025). www.dea.gov
   Details on proposed Special Registration system for telehealth prescribing of controlled substances, including Schedule II provisions for psychiatrists.

3. Healthcare Finance News – ‘Telehealth prescribing of controlled drugs extended through 2025’ by Susan Morse (November 18, 2024). www.healthcarefinancenews.com
   Context on the Ryan Haight Act waiver and DEA extension history during and after the COVID-19 public health emergency.

4. Florida Statutes §456.47 – Use of Telehealth to Provide Services. www.leg.state.fl.us
   Florida state law defining telehealth practice and controlled substance prescribing exceptions (psychiatric disorder exception).

5. Florida Statutes §464.012 – Nurse Practice Act, APRN Prescribing Authority. www.flsenate.gov
   Florida statute specifying APRN scope of practice, Schedule II prescribing limits, and psychiatric nurse exceptions.

Source:

• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=WASHINGTON%20%E2%80%93%C2%A0The%20U,flexibilities%20through%20December%2031%2C%202026
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=Under%20these%20telemedicine%20flexibilities%2C%20DEA,applicable%20federal%20and%20state%20law
• https://www.healthcarefinancenews.com/news/telehealth-prescribing-controlled-drugs-extended-through-2025#:~:text=During%20the%20COVID,person%20evaluation%20of%20that%20patient
• https://www.dlapiper.com/en-th/insights/publications/2024/11/dea-and-hhs-issue-third-temporary-extension-of-telemedicine-flexibilities#:~:text=Further%2C%20as%20the%20Third%20Temporary,monitor%20this%20space%20for%20updates
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=ever%20having%20an%20in,specialized%20medical%20providers%20to%20issue
• https://www.op.nysed.gov/professions/nurse-practitioners/professional-practice/practice-requirements#:~:text=New%20York%20State%20Education%20Law,to%20practice%20under%20physician%20supervision
• https://idfpr.illinois.gov/profs/nursing.html#:~:text=,APN%20Controlled%20Substance
• https://www.op.nysed.gov/professions/nurse-practitioners/professional-practice/practice-requirements#:~:text=Nurse%20practitioners%2C%20however%2C%20must%20practice,or%20certified%20NP%20as%20follows
• https://www.flsenate.gov/laws/statutes/2024/464.012#:~:text=also%20are%20psychiatric%20nurses%20as,455
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=provider%20may%20not%20use%20telehealth,in%20Schedule%20II%20of%20s